What is HC Wainwright’s Forecast for CTXR Q1 Earnings?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Citius Pharmaceuticals in a research note issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino anticipates that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2026 earnings at $0.05 EPS.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01).

Citius Pharmaceuticals Stock Up 7.3 %

Shares of CTXR stock opened at $0.48 on Wednesday. Citius Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $1.07. The firm has a fifty day moving average of $0.45 and a 200-day moving average of $0.61. The firm has a market capitalization of $87.15 million, a price-to-earnings ratio of -1.87 and a beta of 1.66.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTXR. Arkadios Wealth Advisors lifted its holdings in shares of Citius Pharmaceuticals by 33.3% during the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock valued at $100,000 after purchasing an additional 50,000 shares in the last quarter. Wealth Advisory Solutions LLC boosted its holdings in shares of Citius Pharmaceuticals by 33.1% in the third quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after buying an additional 50,000 shares during the period. Point72 DIFC Ltd bought a new stake in Citius Pharmaceuticals in the 2nd quarter valued at $29,000. Cubist Systematic Strategies LLC acquired a new position in Citius Pharmaceuticals in the 2nd quarter worth $69,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Citius Pharmaceuticals during the 2nd quarter worth about $118,000. 16.88% of the stock is owned by institutional investors and hedge funds.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.